This site is intended for healthcare professionals
News

Phase III study of subcutaneous daratumumab combination treatment shows positive response in light chain (AL) amyloidosis.- Janssen R&D

Read time: 2 mins
Last updated:15th Jun 2020
Published:14th Jun 2020
Condition: Amyloidosis
Type: drug
Register free for full access to medthority.com